Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Subscribe To Our Newsletter & Stay Updated
